Storing Foxo4 Dri: Best Practices
Lyophilized Powder
Store at -20°C or lower to maintain stability. The lyophilized form is highly stable due to D-amino acid composition. Keep sealed, away from moisture and light.
Reconstituted Solution
Dissolve in PBS (Phosphate Buffered Saline) or sterile water. Prepare stock solutions at 2 mM or 5 mg/mL. Keep reconstituted solutions on ice and use promptly. Aliquot stock solutions to prevent freeze-thaw cycles which may degrade the peptide despite its protease resistance.
Handling
White lyophilized powder, typically supplied as a TFA (trifluoroacetic acid) salt. Purity: ≥95–98% by HPLC. Identity: Mass Spectrometry (~5358.05 Da). The D-Retro-Inverso modification provides exceptional resistance to proteolytic degradation, with intracellular detection up to 72 hours post-administration.
References
- Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1), 132-147.e16, 2017.
- Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications, 16(1), 5672, 2025.
- Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters, 592(12), 2083-2097, 2018.
- Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging, 12(2), 1272-1284, 2020.
- Hu Z, et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology, 13, 1729166, 2026.
- Huang Y, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology, 9, 677576, 2021.
- Li Y, et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental Gerontology, 195, 112522, 2024.
- Han X, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine, 26(11), 3269-3280, 2022.
- Liu Y, et al. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(10), 2393-2403, 2023.
- Putavet DA, et al. Abstract IA002: Targeting senescence heterogeneity against cancer therapy-resistance and metastases. Cancer Research, 81(5_Supplement), IA002, 2021.
- Meng J, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. JCI Insight, 6(23), e146334, 2021.
- Krimpenfort P, Berns A. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell, 169(1), 3-5, 2017.
- Mandal R, et al. FOXO4 interacts with p53 TAD and CRD and inhibits its binding to DNA. Protein Science, 31(5), e4287, 2022.
- Kong YX, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology, 8(1), 299, 2025.
- van Willigenburg H, de Keizer PLJ, de Bruin RWF. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacological Research, 130, 322-330, 2018.
- Putavet D, et al. Abstract P1-19-02: Repurposing the FOXO4 senolytic against triple-negative breast cancer. Cancer Research, 82(4_Supplement), P1-19-02, 2022.
- Nwankwo N, Okafor I. Bioinformatics procedure for investigating senolytic (anti-aging) agents: A digital signal processing technique. Aging Medicine, 6(4), 338-346, 2024.
- Timucin E, et al. Novel Senolytic Peptides. United States Patent Application, US20200255489A1, 2020.
Related Research Questions
Want the complete research review?
View Full Foxo4 Dri Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.